Connective-Tissue Arteriopathies and Other Rare Nonatherosclerotic Arterial Disorders

51.1Phenotype before repair

The first surgical decision in connective-tissue arteriopathy is not how to repair the artery, but whether the phenotype permits repair at all, and at what threshold the risk of the natural history exceeds the risk created by intervention. In Marfan syndrome, prophylactic aortic-root surgery is deliberately offered at lower diameters than in sporadic thoracic aneurysm disease: commonly at or before 5.0 cm in otherwise lower-risk adults, and in the 4.5–5.0 cm range when additional risk modifiers are present. The practical risk modifiers are the ones that should appear in the operative note and multidisciplinary discussion: documented growth rate, family history of dissection, and the broader clinical picture of inherited thoracic aortic disease rather than diameter alone. ACC/AHA 2022

For the vascular surgeon, “Marfan aorta” should not be used as a shorthand for all inherited aortopathy. A patient with aortic-root enlargement, skeletal habitus, mitral-valve disease, and an FBN1 variant is different from a patient with Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, ACTA2-related disease, or SMAD3-related aneurysms-osteoarthritis syndrome. The consequence is practical: the diameter threshold, the territory imaged, the family members screened, the operation selected, and the tolerance for elective arterial manipulation all change once the phenotype and genotype are clarified. Association Between Genetic 2023 · Genetic screening heritable 2022

In Marfan syndrome, the common operative problem is progressive aortic-root dilation in a patient who may otherwise appear well. The bedside error is to wait for the same diameter used for degenerative aneurysm disease. Once root enlargement approaches the syndrome-specific intervention range, the surgeon should review serial measurements, growth rate, family history, valve morphology, and candidacy for valve-sparing root replacement. Referral to a high-volume aortic center is not cosmetic; the durability of valve-sparing root surgery and the balance between composite valve-graft replacement and valve preservation are strongly dependent on experience. ACC/AHA 2022 · Aortic root surgery 2019

Marfan surveillance also requires attention beyond the aortic diameter. Aortic-root dilation is the dominant cardiovascular feature in children and young adults, and early onset and growth rate shape the likelihood of prophylactic root surgery in early adulthood. Characteristics children young 2013 Mitral-valve prolapse and valve dysfunction should be assessed during echocardiographic surveillance rather than treated as incidental findings, because valve morphology can affect operative planning, longitudinal symptoms, and quality-of-life discussions. Clinical Phenotypic Correlates 2025

SMAD3-related disease is a useful reminder that inherited thoracic aortic disease may announce itself through nonvascular features. Exome sequencing identifies 2011 Families with thoracic aortic aneurysm and early-onset osteoarthritis should prompt consideration of aneurysms-osteoarthritis syndrome and inclusion of SMAD3 in the gene panel. The surgical implication is that the family history may be framed incorrectly as “arthritis plus aneurysm” unless the surgeon deliberately asks about joint disease, early degenerative change, and arterial events across relatives. Genetic screening heritable 2022

Vascular Ehlers-Danlos syndrome is the opposite end of the operative-risk spectrum. In vEDS, arterial rupture is a dominant cause of death, event-free survival declines substantially through middle adulthood, and the patient may have silent arterial lesions before a catastrophic presentation. The threshold problem is therefore not merely “how large is the aneurysm,” but whether an elective procedure will create more danger than observation, surveillance, and emergency preparedness. Vascular Ehlers-Danlos Syndrome 2024 · Assessment arterial damage 2022

The operative posture in vEDS should be conservative unless the event is life- or limb-threatening. Fragile tissues, unpredictable arterial events, and high procedural complication risk make routine elective arterial reconstruction inappropriate in most patients. When intervention is unavoidable, the vascular surgeon should plan for access complications, suture-line failure, arterial tearing, and the need for rapid conversion or damage-control decision-making; the safest operation may be the least anatomically ambitious operation that solves the immediate threat. ACC/AHA 2022 · Diagnosis management vascular 2023

Phenotyping should be documented explicitly. A useful preoperative assessment states the working syndrome, known pathogenic variant if present, arterial territories already imaged, current maximal diameter and growth rate, family history of dissection or rupture, pregnancy considerations when relevant, current medical therapy, and the reason the chosen threshold is being used. This is more than administrative clarity: it prevents the common error of applying sporadic aneurysm thresholds to Marfan syndrome, Marfan thresholds to Loeys-Dietz syndrome, or elective-repair logic to vascular Ehlers-Danlos syndrome. ACC/AHA 2022 · Association Between Genetic 2023

51.2Genetic and family pathways

The genetic pathway begins when the vascular surgeon recognizes that thoracic aortic disease is not behaving like sporadic aneurysm disease. Young age at presentation, family history of thoracic aortic aneurysm or dissection, syndromic features, unusual arterial territory involvement, or a history suggestive of vascular fragility should trigger formal genetic evaluation. The decision should be recorded as a management decision, not a descriptive afterthought, because a confirmed diagnosis changes imaging, thresholds, family screening, and the counseling given before elective or emergency repair. ACC/AHA 2022 · Genetic screening heritable 2022

For patients with suspected heritable thoracic aortic disease, targeted genetic testing is central to evaluation, and cascade screening of first-degree relatives should be organized once a familial pathogenic variant is identified. A practical referral should state the clinical indication, the affected arterial territory, age at first event, family history, and whether the test result is expected to alter operative threshold or surveillance. In relatives, the goal is not simply to attach a label but to identify asymptomatic carriers who should enter imaging surveillance before the first dissection or rupture. ACC/AHA 2022 · Genetic screening heritable 2022

A confirmed genetic diagnosis is not neutral information. Patients with heritable thoracic aortic disease and a confirmed diagnosis have differential outcomes, including younger age at first event and higher rates of dissection in some genetic groups, supporting risk-stratified surveillance and intervention thresholds by gene. The vascular surgeon should therefore avoid documenting “familial TAA” as if it were a single-risk category once a gene-level diagnosis is available. Association Between Genetic 2023

FBN1 interpretation requires particular care because variant class affects confidence in diagnosis and may influence perceived aortic severity. Cysteine-affecting and premature-termination variants are associated with more severe aortic phenotypes than missense variants of uncertain significance, and variant classifications can change as evidence accumulates. Interpretation classification FBN1 2024 In practice, the surgeon should not independently overcall a variant of uncertain significance as Marfan syndrome; collaboration with medical genetics is part of safe operative planning and family counseling.

Medical therapy for Marfan syndrome should be framed as risk modification, not as a substitute for surveillance or timely surgery. Individual-patient-data analyses support both angiotensin receptor blockers and beta blockers for slowing aortic-root growth, with combination therapy offering additive benefit in some subgroups when tolerated. Angiotensin receptor blockers 2022 A practical clinic plan records the chosen agent or combination, tolerability, blood-pressure and heart-rate considerations, and the imaging endpoint used to judge whether the aorta continues to enlarge despite therapy.

The rationale for angiotensin receptor blockade in Marfan syndrome is supported by the interaction of TGF-β signaling and angiotensin II pathways in Marfan aortic disease, while adult and pediatric trials provide the clinical framework for use. Dissecting aortic aneurysm 2023 Losartan methodology in adult Marfan cohorts, long-term follow-up of losartan-treated patients, and irbesartan data from AIMS all support the view that ARB therapy has a modest but clinically relevant role in reducing aortic-root growth. Long-term clinical outcomes 2020 · Irbesartan Marfan syndrome 2019 · Losartan therapy adults 2010 The surgeon should communicate the boundary clearly: medication may slow growth, but it does not remove the need for serial measurement or prophylactic root surgery once syndrome-specific thresholds are reached.

In children and young adults with Marfan syndrome, aortic-root dilation is the principal cardiovascular surveillance target, and the pediatric atenolol-versus-losartan trial framework anchors contemporary discussions of beta blockade versus ARB therapy. Characteristics children young 2013 · Rationale design randomized 2007 The important clinical habit is to establish baseline imaging early, repeat imaging in a way that permits growth-rate calculation, and document whether the patient is progressing toward an adult surgical threshold. Prospective randomized placebo-controlled 2013

Medical therapy in Marfan syndrome: evidence and personalization

Not every promising biomarker or adjunct is ready for operative decision-making. Aortic biomechanical properties such as stiffness and strain appear to track Marfan aortic dilation earlier than diameter alone, and advanced three-dimensional imaging may improve individualized growth-rate tracking, but these measures remain complementary and research-stage rather than stand-alone triggers for surgery. Are aortic biomechanical 2024 · Effects resveratrol 2024 Similarly, resveratrol and other novel pharmacologic adjuncts should be regarded as investigational rather than routine therapy outside trial settings.

The family pathway should be closed-loop. When a pathogenic variant is found, first-degree relatives should be offered cascade genetic testing and, when indicated, surveillance imaging. When no variant is found but the pedigree remains convincing, the surgeon should still document the family-history risk and maintain imaging-based surveillance for relatives according to specialist advice, because panel content, penetrance, and variant reclassification evolve over time. ACC/AHA 2022 · Genetic screening heritable 2022

51.3Gene and territory lanes

A useful way to teach inherited arteriopathy is to separate gene lane from territory lane. The gene lane estimates dissection or rupture behavior, family risk, and surgical threshold; the territory lane determines what must be imaged and what operation is anatomically possible. A patient with FBN1-related Marfan syndrome and root-predominant enlargement is not managed like a patient with Loeys-Dietz syndrome who may dissect at smaller diameters, and neither is managed like a patient with COL3A1-related vascular Ehlers-Danlos syndrome in whom arterial access and suture purchase may be the central hazards. ACC/AHA 2022 · Association Between Genetic 2023

In Marfan syndrome, the dominant lane is often the aortic root, with echocardiography used for root and valve surveillance and cross-sectional MRA or CTA used to map the whole aorta. This combined approach avoids the false reassurance of a stable root when other aortic segments have not been adequately assessed, and it supports operative planning when prior root surgery shifts later risk to distal aortic segments. ACC/AHA 2022 · Are aortic biomechanical 2024

The medical-therapy lane in Marfan syndrome should be individualized rather than doctrinaire. Beta blockers and angiotensin receptor blockers both slow aortic-root growth, and tolerability, age, phenotype, blood pressure, and the need for combination therapy should guide selection. The failure mode to anticipate is therapeutic complacency: a patient may be “on appropriate medication” and still demonstrate progressive enlargement that requires prophylactic surgery. Angiotensin receptor blockers 2022 · Long-term clinical outcomes 2020

Loeys-Dietz syndrome occupies a lower-threshold surgical lane than Marfan syndrome. The reason is not only the name of the syndrome but the gene-specific phenotype, with TGFBR1, TGFBR2, TGFB2, and TGFB3 associated with differing severity and refinement of operative thresholds. In practice, the surgeon should ask for the specific gene, not merely the label “Loeys-Dietz,” before concluding that a root diameter is safe for continued surveillance. ACC/AHA 2022 · Association Between Genetic 2023

SMAD3-related aneurysms-osteoarthritis syndrome belongs in the same disciplined gene-and-territory framework. Exome sequencing identifies 2011 The clue may be early-onset osteoarthritis in a family with thoracic aortic aneurysm and dissection, but the vascular work is to identify the aortic and non-aortic arterial territories at risk, enter relatives into cascade pathways, and avoid assuming that a Marfan-negative family has no inherited aortopathy. Genetic screening heritable 2022

Vascular Ehlers-Danlos syndrome is a territory-wide fragility disorder rather than a simple aneurysm-size disorder. Imaging studies document widespread, often clinically silent arterial lesions, including aneurysms, dissections, and fistulae, supporting baseline and periodic head-to-pelvis arterial imaging. Assessment arterial damage 2022 The failure mode is discovering the full arterial burden only at the time of rupture, when access planning, landing zones, and bailout options are all constrained by tissue fragility. Diagnosis management vascular 2023

The intracranial territory should not be ignored in Marfan syndrome. A higher prevalence of unruptured intracranial aneurysms than in the general population supports discussion of one-time intracranial vascular imaging as part of comprehensive workup. Prevalence unruptured intracranial 2023 Once an intracranial aneurysm is found, however, rupture-risk decisions should follow intracranial-aneurysm principles rather than automatic repair based solely on the Marfan diagnosis.

Pediatric vascular Ehlers-Danlos syndrome also requires a distinct lane. Early diagnosis in children with suggestive clinical or family features enables family counseling, activity and sport guidance, and early surveillance strategies. Vascular Ehlers-Danlos syndrome 2025 The surgeon’s role is usually not to operate, but to ensure that the child and family are connected to a specialist pathway before the first arterial event. Diagnosis management vascular 2023

Pregnancy creates a separate territory-and-timing lane in vascular Ehlers-Danlos syndrome. Women with vEDS contemplating pregnancy require preconception counseling because pregnancy and delivery carry materially increased risks of arterial and uterine rupture. Pregnancy Delivery Outcomes 2026 For the vascular surgeon, the relevant preparation is not elective arterial repair by default, but a tertiary-care plan that integrates maternal-fetal medicine, anesthesia, vascular surgery, emergency access, and a realistic discussion of maternal risk. Diagnosis management vascular 2023

51.4Clinical integration, follow-up, and evidence boundaries

Follow-up in inherited arteriopathy is an active treatment plan, not passive observation. Each visit should answer five questions: has the maximal arterial diameter changed, has the growth rate changed, has a new arterial territory been identified, has the genetic or family-risk interpretation changed, and has the patient crossed a syndrome-specific threshold for referral, medication adjustment, or prophylactic repair. This structure is especially important because modern guidance uses lower thresholds for Marfan syndrome than sporadic aneurysm disease and still lower, gene-informed thresholds for Loeys-Dietz syndrome. ACC/AHA 2022 · Association Between Genetic 2023

For Marfan syndrome, longitudinal management should combine medical therapy, root and valve surveillance, whole-aorta mapping, and timely referral for root surgery. Valve-sparing root replacement is a durable option in eligible candidates in experienced centers, while composite valve-graft replacement remains appropriate when valve preservation is unsuitable. The decision should include patient age, valve morphology, root size, growth rate, family history, center expertise, and the long-term implications of anticoagulation or valve reintervention. ACC/AHA 2022 · Clinical Phenotypic Correlates 2025 · Aortic root surgery 2019

ARB and beta-blocker therapy should be continued when tolerated and clinically appropriate, but follow-up must preserve the distinction between slower growth and eliminated risk. Individual-patient-data meta-analysis supports ARB and beta-blocker benefit, AIMS supports an ARB class effect with irbesartan, and long-term losartan follow-up supports sustained tolerability and slowing of root growth. Angiotensin receptor blockers 2022 · Long-term clinical outcomes 2020 · Irbesartan Marfan syndrome 2019 Escalation remains necessary when growth continues, thresholds are reached, or additional clinical risk factors emerge.

Loeys-Dietz follow-up should be more aggressive than Marfan follow-up when applying aortic-disease guidance, because dissection risk may occur at smaller diameters and thresholds are refined by genotype. In a surgical clinic, this means the follow-up letter should specify the gene when known, the current diameter, the interval growth, and the rationale for continued surveillance versus prophylactic repair. A generic phrase such as “connective-tissue disease, observe” is inadequate for a syndrome in which gene-specific severity modifies thresholds. ACC/AHA 2022 · Association Between Genetic 2023

For vascular Ehlers-Danlos syndrome, the safest longitudinal plan is usually centralized surveillance and emergency readiness rather than elective reconstruction. UK specialist-service experience describes unpredictable arterial events clustering in young adulthood and supports centralized follow-up with rapid emergency-access pathways. Imaging assessment demonstrates widespread silent arterial damage, supporting baseline and periodic head-to-pelvis surveillance, although intervals are not standardized and should be individualized in specialist care. Diagnosis management vascular 2023 · Assessment arterial damage 2022

When vEDS patients present with arterial events, the intervention threshold should be life- or limb-threatening disease rather than anatomic tidiness. Elective open or endovascular intervention is generally avoided because of fragile tissues and high complication risk, although selected interventions may be undertaken in expert centers when the risk of nonintervention is unacceptable. The operative plan should minimize arterial manipulation, anticipate access failure, and prioritize immediate control of hemorrhage or ischemia over complete reconstruction of every abnormal segment. ACC/AHA 2022 · Diagnosis management vascular 2023

Celiprolol deserves a careful, region-specific discussion in vEDS. Vascular Ehlers-Danlos Syndrome 2024 Long-term cohort data suggest reduced arterial event rates in treated patients, and specialist programs report its use in some cohorts, but availability and adoption vary. The vascular surgeon should not present celiprolol as a universally available cure; it is a potential medical-risk modifier to be discussed with a specialist center while surveillance and emergency planning remain essential. Diagnosis management vascular 2023

Pregnancy counseling in vEDS should occur before conception whenever possible. The risk of arterial and uterine rupture makes pregnancy a high-risk event requiring maternal-fetal medicine, vascular surgery, anesthesia, and tertiary obstetric planning. Pregnancy Delivery Outcomes 2026 In women who present already pregnant, the vascular surgeon’s contribution is to define known arterial lesions, establish emergency access pathways, and avoid routine elective arterial intervention unless a specific life-threatening indication emerges. Diagnosis management vascular 2023

Quality of life should be part of vascular follow-up in Marfan syndrome. Registry data show reduced physical quality of life compared with population norms, especially among patients with prior aortic intervention or musculoskeletal involvement. Marfan Syndrome Quality 2017 This matters surgically because recovery expectations, activity guidance, medication tolerance, reintervention anxiety, and family counseling all affect adherence to surveillance and the timing of elective repair.

The evidence boundary must be stated plainly in clinical reasoning. Diameter thresholds are best established for aortic-root disease in common inherited syndromes, while biomechanical imaging metrics, novel pharmacologic adjuncts, and some genotype-specific thresholds continue to evolve. The responsible surgical stance is to use established syndrome-specific thresholds where available, seek expert genetic interpretation, reanalyze variants when appropriate, and avoid converting promising research signals into operative triggers before they are validated. Are aortic biomechanical 2024 · Effects resveratrol 2024 · Genetic screening heritable 2022

A final practical principle is that inherited arteriopathy care should be documented as a longitudinal program. The record should identify the syndrome or suspected syndrome, genetic result and variant classification, relatives offered cascade testing, arterial territories imaged, current measurements and growth rates, medication strategy, pregnancy or pediatric considerations when relevant, emergency plan for vEDS, and the next decision threshold. This documentation is what allows the next surgeon, emergency physician, or trainee to understand why a 4.7-cm root may merit surgery in one patient, surveillance in another, and why an apparently repairable vEDS lesion may be deliberately observed. ACC/AHA 2022 · Diagnosis management vascular 2023 · Interpretation classification FBN1 2024